Remdesivir Global Market to Observe Highest Growth of $14.12 Billion with an Excellent CAGR of 21.4% By 2028 | Cipla Limited, Pfizer Inc., Berry Global Group, Hetero Labs Limited, Mylan N.V.

"The new report published by The Business Research Company, titled ""Remdesivir Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the remdesivir market size has grown exponentially in recent years. It will grow from $4.95 billion in 2023 to $6.49 billion in 2024 at a compound annual growth rate (CAGR) of 31.2%. The remdesivir market size is expected to see exponentially grown in the next few years. It will grow to $14.12 billion in 2028 at a compound annual growth rate (CAGR) of 21.4%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3253&type=smp

Role Of Government Expenditure In Driving Remdesivir Market Growth
The increasing government expenditure is expected to propel the growth of the remdesivir market going forward. Government expenditure, also known as government spending, refers to the total amount of money that a government or public sector entity allocates and disburses to finance its operations, programs, services, and projects. Government expenditure is instrumental in the growth and accessibility of Remdesivir, especially during public health crises. By providing funding, regulatory support, purchasing power, and research investments, governments can contribute to the availability and affordability of this critical antiviral medication. For instance, in July 2023, according to the Government Digital Service, a UK-based government body, the central government's own current spending on services increased from $876.47 billion to $963.74 billion in 2022-23. The amount spent on capital projects for services rose from $81.37 billion in 2021-2022 to $104.72 billion in 2022-2023 dollars. Therefore, the increasing government spending is driving the growth of the remdesivir market.

Gilead's New FDA-Approved Drug Veklury (Remdesivir) To Treat Covid-19
Major companies operating in the remdesivir market are receiving FDA approvals for new drugs such as Veklury (Remdesivir) to increase their profitability in the market. Veklury (remdesivir) is an antiviral medication used to treat COVID-19 in adults and pediatric patients who are at least 28 days old and weigh at least 3 kg. For instance, in January 2022, Gilead Sciences Inc., a US-based pharmaceuticals company announced that Food and Drug Administration has approved its new drug called Veklury (Remdesivir). Veklury is used to treat mild to moderate COVID-19 symptoms in adults and children who are hospitalized or not and are at high risk for developing severe COVID-19, including hospitalization or death.

The remdesivir market covered in this report is segmented -
1) By Route Of Administration: Oral, Intravenous
2) By Dosage Form: Tablets, Frozen Solution, Lypholized Solution
3) By Distribution Channel: Hospitals, Clinics, Drug Stores/Pharmacies, Online, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=3253&type=discount

Major companies operating in the remdesivir market include Gilead Sciences Inc., BrightGene Bio-Medical Technology Co Ltd, Hainan Haiyao Co. Ltd., Sichuan Kelun Pharmaceutical Co. Ltd., Hunan Warrant Pharmaceutical, Cipla Limited, Pfizer Inc., Merck & Co. Inc., Cayman Chemical Company, Dr Reddy's Laboratories Ltd., Inovio Pharmaceuticals, Shenzhen BORUI Pharmaceutical Technology Co. Ltd., Berry Global Group, Hetero Labs Limited, Mylan N.V., Jubilant Generics, Zydus Cadila Health Care Limited, Syngene International Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Teva Pharmaceutical Industries, Ferozsons Laboratories Limited, Jubilant Life Sciences, Laurus Labs, Macleods Pharmaceuticals, Natco Pharma, Sandoz Group AG, Strides Pharma Science Limited, Torrent Pharmaceuticals, Beximco Pharmaceuticals Ltd., Fresenius Kabi, Gland Pharma Limited, Hikma Pharmaceuticals, Lark Laboratories

Contents of the report:
1. Executive Summary
2. Remdesivir Market Report Structure
3. Remdesivir Market Trends And Strategies
4. Remdesivir Market - Macro Economic Scenario
5. Remdesivir Market Size And Growth
…..
27. Remdesivir Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/remdesivir-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.